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1. Introduction 
Pituitary adenomas are typically benign, slow-growing tumors that arise from cells in the 
pituitary gland. Those are classified based on secretory products (1). The functioning 
(endocrine-active) tumors include almost 70% of pituitary tumors which produce 1 or 2 
hormones that are measurable in the serum and cause definite clinical syndromes that are 
classified based on their secretory product(s). Non-functioning adenomas are endocrine-
inactive tumors (2). Because of the physiologic effects of excess hormones, functioning 
tumors usually present earlier than non-functioning adenomas (3). On the other hand, mass 
effect from large pituitary adenomas (often due to endocrine-inactive tumors) may lead to 
pressure symptoms such as headaches, visual field defects (typically loss of peripheral 
vision), cranial nerve deficits, hypopituitarism (compression of normal pituitary gland), 
pituitary apoplexy (sudden bleeding or infarction from outgrowing tumor blood supply), or 
stalk dysfunction (4). Compression of pituitary stalk is termed “stalk effect” which can cause 
a mild elevation in prolactin, and must be differentiated from a prolactinoma (5).  
The purpose of this chapter is to review all types of functioning pituitary adenoma 
(prolactin, ACTH, GH, TSH, LH and FSH secreting) from studies indexed in PubMed. We 
describe the symptoms, epidemiology, diagnosis, management, outcome and complications 
of each. 
2. Prolactinoma 
This type of pituitary adenoma arises from neoplastic transformation of anterior pituitary 
lactotrophs and produces an excessive amount of hormone prolactin. A prolactinoma is the 
most common cause of chronic hyperprolactinemia once pregnancy, primary 
hypothyroidism, and drugs that elevate serum prolactin levels have been excluded (6).  
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2.1 Symptoms 
In female patients, even small prolactinomas can cause irregular menstrual periods or 
complete loss of menses. Higher prolactin levels lead to galactorrhea in women, whereas 
men may experience gynecomastia. In male patients, altered spermatogenesis with 
oligospermia and infertility may be found; galactorrhea and gynaecomastia are much less 
frequent. Hypogonadism, reduced libido and infertility are the most frequent symptoms in 
both genders. Patients can also present with osteopenia and osteoporosis (due to estrogen 
and testosterone deficiency, not due to the elevated prolactin itself). Large prolactinomas, 
more commonly found in men, may cause mass effect from the tumor (5-9). 
2.2 Epidemiology  
The estimated prevalence of prolactinoma is 100 per million adults (10). Prolactinomas are 
the most common hormone-secreting pituitary tumors, representing approximately 40% of 
all pituitary tumors (8, 11, 12). Recent data show a high prevalence of prolactinoma in the 
general population, 3-5 times more than the previously reported ones (13). The incidence of 
prolactinomas varies with age and sex; these tumors occur with the highest frequency in 
women aged 20–50 years, at which point the ratio between the sexes is estimated to be 10:1. 
In adults aged >60 years, prolactinomas occur with a similar frequency in both sexes (12). 
Men generally have macroadenomas (≥10mm diameter) whereas women generally have 
microadenomas (<10mm) (6, 13, 14). The mean age at diagnosis is 10 years greater in men. 
This delay possibly accounts for their greater incidence of macroprolactinomas with visual 
field defects and hypopituitarism at first presentation (15). 
2.3 Diagnosis 
A serum prolactin level is acquired in response to a specific presentation, including 
symptoms of hyperprolactinemia (such as amenorrhea and galactorrhea) it may also be an 
integral part of an infertility assessment. An initial level above the normal range should be 
followed by a repeat level from a blood sample drawn in the morning with the patient in a 
fasting state. When hyperprolactinemia is confirmed, a cause for the disorder needs to be 
sought. This involves a careful history and examination, followed by laboratory tests and 
diagnostic imaging of the sella turcica. If serum prolactin levels are above 200 µg/L, a 
prolactinoma is almost certainly the underlying cause, but if levels are lower, the differential 
diagnoses include pregnancy, treatment with drugs (such as neuroleptics) that reduce 
dopaminergic effects on the pituitary, compression of the pituitary stalk by other pathology, 
primary hypothyroidism, renal failure, cirrhosis, chest wall lesions, or idiopathic 
hyperprolactinemia. In the absence of such causes, radiologic imaging of the sella turcica is 
necessary to establish whether a prolactinoma or other lesions are present (4, 6, 16). 
2.4 Management 
The main purpose of treating prolactinomas, both micro- and macroprolactinomas, are to 
suppress excess hormone secretion and its clinical effects, to remove the tumor mass, and to 
prevent disease return or progression (16, 17). If there is no indication for therapy (such as 
amenorrhea, infertility or bothersome galactorrhea), microadenomas may be followed 
conservatively, and regular follow-up with serial prolactin measurements and pituitary 
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imaging should be organized (6, 16). Most prolactinomas can be effectively treated with 
dopaminergic drugs as primary management. For most patients,  medical therapy produces 
normalization of prolactin secretion, gonadal function, and considerable tumor shrinkage in 
the majority (16). The most commonly used dopamine agonists are bromocriptine, 
cabergoline (ergot derivatives) as well as quinagolide (a non-ergot derivative) (4, 18). 
Bromocriptine (D2 receptor agonist and D1 receptor antagonist) is the oldest drug for 
medical treatment of prolactinomas, and normalizes prolactin levels in 80-90% of 
microprolactinomas and 70% of macroprolactinomas. Tumor-mass shrinkage and 
improvement of visual-field deficits are commonly achieved in macroprolactinomas. 
Bromocriptine frequently can cause several side effects such as nausea, vomiting, postural 
hypotension, headache and dizziness (12). Cabergoline (a selective D2 receptor agonist) is 
very effective and well tolerated in more than 90% of the patients with either 
microprolactinomas or macroprolactinomas. Cabergoline treatment also induces tumor 
shrinkage in most macroprolactinomas. If patients have not previously been treated with 
other dopamine agonists, tumor shrinkage is more evident (17). When comparing the 
plasma half-life, efficacy and tolerability of these drugs, cabergoline seems to have the most 
favorable profile, followed by quinagolide (16). As a well tolerated and effective therapy 
and a simple dosing regimen, quinagolide (selective D2 receptor agonist) can also be 
considered a first-line therapy in the treatment of hyperprolactinaemia (19). Pergolide (a D1 
and D2 agonist) normalizes prolactin excess and reduces tumor size in recently diagnosed 
patients with macroprolactinomas with a potency of about 100-fold that of bromocriptine 
(20). However pergolide as approved treatment for prolactinomas was withdrawn in 2007 
because of adverse effects on cardiac valves (12).  
If prolactin levels are well controlled with dopamine agonist therapy, gradual tapering of 
the dose to the lowest effective amount is recommended, and in some cases medication can 
be stopped after several years. Evidence to date suggests that cabergoline and quinagolide 
appear to have a good safety profile for women who wish to conceive, but hard evidence 
proving that dopamine agonists do not provoke congenital malformations when taken 
during early pregnancy is currently only available for bromocriptine. Once pregnant, 
dopamine agonist therapy should be immediately stopped, unless the growth of a 
macroprolactinoma or pressure symptoms is likely to occur (4, 16). Hyperprolactinemia may 
recur after dopamine agonist withdrawal in a considerable proportion of patients. The 
probability of successful treatment was highest when cabergoline was used for at least two 
years (21). 
Surgery is generally used as second-line treatment in prolactinomas (22). Transsphenoidal 
surgery is an alternative for patients who are intolerant of or resistant to dopamine agonists 
or when hyperprolactinemia is caused by non-prolactin-secreting tumors compressing the 
pituitary stalk (4). 
Because pituitary adenomas respond well to radiation, radiotherapy has been a part of their 
management for the past three decades (23). Radiotherapy is given if both pharmacologic 
therapy and surgery fail (4, 16). However, Sasaki et al. reported that the local control rate for 
secreting adenomas by radiotherapy is unsatisfactory (23). 
Gamma knife radiosurgery can be offered as a safe and effective treatment option especially 
for those patients with recurrent or residual pituitary adenoma after surgical removal. The 
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tumor control rate after gamma knife radiosurgery for pituitary adenomas is equivalent to 
fractionated radiation therapy (24).  
Some experimental treatments have been attempted, such as somatostatin analogues, hybrid 
molecules (both somatostatin and a dopamine agonist in a single molecule), selective 
estrogen receptor modulators, prolactin-receptor antagonists, and temozolomide are utilized 
in selected case reports or in trial settings. These have not yet been included in standard 
medical practice (12).   
2.5 Outcome 
The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism 
through the normalization of hyperprolactinemia and control of tumor mass (11). Medical 
and surgical therapies generally have excellent results, and most prolactinomas are well 
controlled or even cured in some cases (19). Dopamine agonists are the preferred therapy for 
prolactinomas because of the risk of recurrent hyperprolactinemia that accompanies 
transsphenoidal surgery (25, 26). Dopamine agonists are the first line of therapy for 
macroprolactinomas, resulting in normalizing prolactin levels in 85%, inducing tumor 
shrinkage in 57%, and long-term remission rates in 22% of the patients (11, 27).  
Surgery should be reserved for patients with dopamine agonist resistance or intolerance. 
Success rates after surgical treatment of microadenomas range from 73–90% and 30–50% for 
macroadenomas, with little morbidity and near zero mortality (28). However, subsequent 
relapse is possible in up to 20% of the cases (22). Surgical outcomes are highly dependent 
upon the expertise and experience of the neurosurgeon (11, 22).  
Following radiotherapy the prevalence of subsequent hypopituitarism is high; therefore, 
this therapy should be carefully considered, and rather be indicated for mass control than 
for hyperprolactinemia (27). 
Overall, patients with pituitary adenoma treated with surgery and radiotherapy have an 
increased risk of cerebrovascular motrtality compared to the general population, which 
mirrors the increased incidence of stroke (29).  
2.6 Complications 
As mentioned in the symptoms section, prolactinomas left untreated may lead to various 
complications. In both women and men, prolactinoma can cause reduced libido, infertility 
and osteoporosis. Women with prolactinoma may experience complications during 
pregnancy. A woman who has a large prolactinoma and becomes pregnant may experience 
additional pituitary growth and associated mass effect. Prolactinoma may also lead to 
impaired glucose tolerance and diabetes. If tumor grows large enough, prolactinoma may 
cause visual loss, headache and hypopituitarism. Disturbances of the haemostatic system 
and dyslipidemia may lead to excess mortality in patients with prolactinoma (5-9, 30, 31). 
3. ACTH secreting PA 
Approximately 80% of the cases of Cushing’s syndrome are due to the excessive secretion of 
adrenocorticotropic hormone (ACTH). This is usually (60-80%) due to a pituitary 
corticotroph adenoma and is defined as Cushing’s disease (2, 32).  
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3.1 Symptoms 
Cushing's syndrome refers to clinical manifestations induced by chronic exposure to excess 
glucocorticoids. The most common symptom of glucocorticoid excess is centripetal fat 
deposition which is frequently the initial symptom of the patient. 
Fat accumulates in the face as well as supraclavicular and dorsocervical fat pads, resulting 
in a typical moon face and buffalo hump, which is most often accompanied by facial 
plethora. Fat also accumulates over the thorax and the abdomen, which becomes 
protuberant (33).  
Other symptoms and signs include obesity; protein-wasting features such as skin thinning, 
large and purple abdominal striae, multiple ecchymotic lesions or purpura generated by 
minimal trauma, lower limb edema, spontaneous ruptures of tendons, slow healing of 
minor wounds, muscle atrophy, particularly in the lower limbs; bone wasting such as 
osteoporosis, pathological fractures, kyphosis and loss of height (34, 35); impaired 
protection mechanism against infections (36);  high blood pressure and cardiovascular 
complications (37, 38); hirsutism; gonadal dysfunction (39); psychic disturbances such as 
anxiety, irritability, sleep disorders, depression, maniac disorders, delusions and/or 
hallucinations (40); and decreased short-term memory and cognition (41). 
3.2 Epidemiology 
The prevalence of Cushing’s disease is approximately 40 per million. ACTH-producing 
adenomas comprise 10-20% of pituitary adenomas (42). Cushing’s disease is nine times 
more common in women than men(2).  
3.3 Diagnosis 
The clinical history is important to assess the general impact of hypercortisolism on organs 
and systems as well as to guide suspicion toward more aggressive entities such as the 
ectopic ACTH syndrome or to detect an iatrogenic etiology of Cushing's syndrome (43). 
Initial diagnosis is performed using tests such as urinary free cortisol, nocturnal salivary 
cortisol and 1 mg dexamethasone suppression that are sensitive but not specific, and still 
require established assessment criteria(44). A dexamethasone- corticotrophin releasing 
hormone (CRH) test can discriminate between Cushing's syndrome and pseudo-Cushing's 
syndrome. If ACTH is elevated, combinations of high-dose dexamethasone tests, 
CRH/desmopressin tests, and pituitary magnetic resonance imaging can indicate a pituitary 
source. Discrimination from an ectopic ACTH tumor often requires inferior petrosal sinus 
sampling to confirm the source of ACTH. If ACTH is low, adrenal computed tomography 
will identify the adrenal lesion(s) implicated. Some cortisol-producing adrenal tumors or, 
more frequently, bilateral macronodular hyperplasia, are under the control of aberrant 
membrane hormone receptors, or the altered activity of ectopic receptors (43-46). 
Sophisticated imaging and isotopic techniques play a significant role in locating the source 
of ACTH in ectopic syndromes but are not always effective. In general, biochemical and 
imaging tests should be combined in order to assess different mechanisms and perspectives 
of the syndrome. Rigorous methodology is essential to obtain accurate results, allowing a 
correct diagnosis and in improving therapeutic performance in this devastating disease (43). 
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3.4 Management 
The best treatment option for Cushing's disease is when the responsible corticotroph adenoma 
can be entirely removed surgically by the trans-sphenoidal approach, with sufficient skill to 
preserve normal anterior pituitary function (32, 46). This induces remission in approximately 
80% of the patients, but long-term relapse occurs in up to 30% of these cases (45). The choice of 
second-line therapy remains controversial (46). Repeat surgery can be successful when 
residual tumor is detectable on magnetic resonance imaging; however, it carries a high risk of 
hypopituitarism. The histological pseudocapsule of a pituitary adenoma is a layer of 
compressed normal anterior lobe that surrounds the adenoma and can be used during surgery 
to identify and guide the removal of the tumor. With this approach, the overall remission rate 
is high and the rate of complications is low (47). Radiotherapy combined with ketoconazole or 
radiosurgery was recently found effective, but a longer-term evaluation of hypopituitarism 
and brain function is required. As soon as residual tumor progresses, surgery and 
radiotherapy should be initiated. Various drugs which inhibit steroid synthesis (ketoconazole, 
metyrapone, aminoglutethimide, mitotane) are sometimes temporarily effective for rapidly 
controlling hypercortisolism either in preparation for surgery, after the unsuccessful removal 
of the etiologic tumor, or while awaiting the full effect of radiotherapy or more definitive 
therapy (45). Other modes of radiotherapy (heavy particles, stereotactic radiosurgery with 
gamma knife) are limited to specialized centers. Despite initial enthusiasm for gamma knife 
(48), a relapse rate of up to 20% has been reported following treatment. It may, however, be 
more rapid than conventional radiotherapy in onset of lowering cortisol levels (49).  
3.5 Outcome 
The long-term follow-up of patients treated for Cushing's disease should include the 
adequate replacement of glucocorticoids and other hormones, treatment of osteoporosis, 
and detection of long-term relapse of Cushing's disease (45). Following pituitary surgery, 
careful ongoing expert endocrine assessment is mandatory, as the incidence of relapse 
increases with time and also with the increasing rigor of the endocrine evaluation. (50). 
3.6 Complications 
Today, cardiovascular and psychiatric co-morbidities still remain the major life-threatening 
complication. The final prognostic criterion for Cushing's syndrome lies in the severity of 
the hypercortisolism and the aggressiveness of the responsible tumor (37, 46). Bone wasting 
results in generalized osteoporosis. The prevalence of bone demineralisation assessed by 
bone mineral density using dual energy X-ray absorptiometry is about 40% (51). 
Compression fractures of the spine are evident on plain radiographs in about 20% - 80% of 
the patients, depending on the studies, and almost half the patients complain about 
backache. Kyphosis and loss of height, sometimes dramatic, are frequent. Pathological 
fractures can occur elsewhere, particularly in the ribs, feet and pelvis (36). Transient features 
of brain atrophy can disappear after cure (52). Impaired quality of life may persist years 
after controlling hypercortisolism (53).  
4. GH secreting PA 
Excessive secretion of growth hormone (GH) is responsible for acromegaly (54). This disease 
is almost always due to a GH-secreting pituitary adenoma. It is distinguished by a gradual 
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progressively acquired somatic disfigurement (primarily involving the face and extremities) 
and leads to acromegaly: a disorder of disproportionate tissue, skeletal, and organ growth 
(55, 56). 
4.1 Symptoms 
Because of the insidious onset and slow progression, acromegaly is frequently diagnosed 
from four to more than ten years after its onset (57). Patients usually display coarsened facial 
appearance, acral enlargement, increased skin thickness and soft tissue hyperplasia. Other 
manifestations include increased sweating, goiter, joint involvement, carpal tunnel 
syndrome, visual abnormalities, headache, colon polyps, sleep apnea, reproductive 
disorders, metabolic disturbances (hypertriglyceridemia, reduced insulin sensitivity), and 
cardiovascular disease (cardiac hypertrophy, hypertension, arrhythmias, and 
cardiomyopathy) (57-59). 
4.2 Epidemiology 
The prevalence is estimated to be 40-130 per million inhabitants, with 3-4 new cases per 
million populations per year (55, 58). It is most often diagnosed in middle-aged adults 
(average age 40 years). Men and women are equally affected (57).  
4.3 Diagnosis 
The measurement of fasting or random GH and of Insulin-like Growth Factor 1 (IGF-1) are 
baseline biochemical criteria for the diagnosis of acromegaly. A random GH level lower 
than 0.4 μg/l and an IGF-1 value in the age- and sex-matched normal range exclude the 
diagnosis of acromegaly. When these two parameters are dissonant, a 75 gram oral glucose 
tolerance test (OGTT) should be performed: a fall of serum GH to 1 μg/l or less within two 
hours will exclude acromegaly (60, 61). 
Measurement of circulating GH-releasing hormone (GHRH) is the preferred test for the 
differential diagnosis between GH-secreting pituitary adenoma and ectopic GHRH 
secretion. Stimulatory tests (thyroid releasing hormone (TRH) stimulation test or 
gonadotropin releasing hormone (GnRH) stimulation test) provide no advantage over 
OGTT, and their use is not recommended for diagnosis (58). 
Acromegaly is caused by an adenoma of the pituitary gland in more than 98% of all patients. 
The size of the tumor and its expansion should be documented by MRI.  If the tumor 
expands into the suprasellar space and/or laterally beyond the cavernous sinus, an 
ophthalmological assessment is suggested to determine the possible impairment of the 
visual field and function of oculomotor nerves (58). 
4.4 Management 
The goal of treatment is to relieve symptoms, to obtain control of local tumor mass, and to 
reduce morbidity and mortality. Treatment options include surgery, medical therapy and 
radiotherapy. Transsphenoidal surgery is the first choice of treatment when a definitive cure 
can be achieved, mainly in the cases of microadenomas and when decompression of 
surrounding structures (optic chiasm, ophthalmic motor nerves) is indicated. This treatment 
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is the first-line therapy except when the macroadenoma is giant or if surgery is contra-
indicated.  Primary medical therapy should be conducted in patients bearing 
macroadenomas with significant lateral extension. In addition, preoperative primary 
medical therapy may result in tumor shrinkage, facilitating tumor resection, and may 
reduce preoperative complications due to GH excess. Within the spectrum of medical 
therapy, long-acting somatostatin analogues (somatostatins) are considered as primary 
therapy. Treatment with somatostatins results in GH control in about 60% of the cases. 
Somatostatins also induce tumor contraction in 30-50% of the patients, most effectively 
when applied as first-line treatment. Prolonged treatment with somatostatins is safe and 
well tolerated. Octreotide and lanreotide (two currently available somatostatins) appear to 
have equal effectiveness. In patients with suboptimal clinical and biochemical response to 
somatostatins, combination therapy with dopamine receptor agonists or pegvisomant (a 
new GH-receptor antagonist) typically leads to effective disease control. New developments 
in the medical therapy of acromegaly include the universal somatostatin receptor agonist 
pasireotide, and chimerical compounds that interact with both somatostatin and dopamine 
receptors with synergizing effects on GH secretion (54, 58, 62, 63). 
If surgery fails, medical therapy should be started or reinstated. Dopaminergic drugs might 
be considered for a small group of patients with mildly elevated GH/IGF-1 levels or 
harboring GH-prolactin co-secreting adenomas (64, 65). The use of radiotherapy 
(fractionated, or by gamma-knife) appears to be justified as a treatment of last resort in 
patients with tumors progressively growing and unresponsive to somatostatins, and in a 
small group of patients who bear aggressive pituitary adenomas invasive of local structures 
including the cavernous sinus and even the temporal lobes. These tumors occur more 
frequently in younger patients, for whom the concerns about radiation-dependent 
hypopituitarism and second tumor formation are higher. Therefore several considerations 
must be taken into account when choosing an individualized treatment program for each 
patient (63, 66). 
4.5 Outcome 
Rheumatologic, cardiovascular, respiratory and metabolic consequences are major factors 
that determine the prognosis (55). The control of GH and IGF-1 secretion is the main goal of 
treatment, since normalization of these two parameters is the most significant determinant 
of reversing the increased mortality rate of the patients. The outcome of transsphenoidal 
surgery is far better for microadenomas (80-90%) than for macroadenomas (less than 50%), 
which unfortunately represent more than 70% of all GH-secreting pituitary tumors. 
Therefore, pituitary surgery is the first line treatment for microadenomas (58). Indeed, 
survival in acromegaly is restored to that observed in the general population after correction 
of GH/IGF-1 hypersecretion, while morbidity (obstructive sleep apnea, carpal tunnel 
syndrome, cardiac dysfunction, and diabetes mellitus) is markedly improved by lowering 
IGF-1 levels(67). 
4.6 Complications 
Acromegaly is a slowly progressive disease characterized by a 30% increase of mortality rate 
for cardiovascular disease (atherosclerosis, cardiomyopathy), respiratory complications, 
arthrosis and malignancies. Patients with acromegaly display an enhanced mortality rate, 
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cardiovascular disease represents the cause of death in 60%, respiratory disease in 25% and 
malignancies in 15% of the cases. High GH levels, high blood pressure and heart disease 
represent the major negative survival determinants in acromegaly, whereas symptom 
duration, diabetes mellitus and cancer play a minor role in determining mortality (54, 58). If 
the condition is untreated, enhanced mortality due to cardiovascular, cerebrovascular, and 
pulmonary dysfunction is associated with a 30% decrease in life span (56). 
5. TSH secreting PA 
Thyroid stimulating hormone (TSH) secreting pituitary adenomas are a rare cause of 
secondary or central hyperthyroidism (68, 69). The pathogenesis of TSH-secreting-adenomas 
is indefinite and no definite role for various oncogenes has been demonstrated (70). Based 
on the Clarke et al. study, these tumors are often delayed in diagnosis, are frequently 
macroadenomas and plurihormonal in terms of their pathological characteristics, have a 
heterogeneous clinical picture, and are difficult to treat (71). Sometimes mixed pituitary 
tumors co-secrete TSH, growth hormone and prolactin (70). 
5.1 Symptoms 
Because of the long standing duration of the disease, patients present mild or moderate 
signs of hyperthyroidism and can rarely be asymptomatic (68, 72, 73). In addition, mass 
effects of the pituitary tumor such as loss of vision and visual field defects may be occurred 
(70, 73). Moreover, hyperthyroid features can be eclipsed by those of acromegaly in patients 
with mixed TSH/GH adenomas, thus emphasizing the importance of systematic 
measurement of TSH and free thyroxin (FT4) in patients with pituitary tumor (74). 
5.2 Epidemiology  
TSH secreting tumors account for 0.9 to 2.8% percent of all pituitary adenomas. The 
diagnosis of these tumors has been increasing in the past 20 years (69). Most patients have 
macroadenomas, and microadenomas are exceptional (75).  
5.3 Diagnosis 
Hormonal evaluation shows increased free thyroid hormone concentration with detectable, 
normal or increased serum TSH level, raising the differential diagnosis of pituitary 
resistance to thyroid hormone (72). Ultrasensitive TSH assays allow a clear distinction 
between patients with suppressed and those with non-suppressed circulating TSH 
concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic 
nodular goiter) and those with central hyperthyroidism (TSH-secreting adenomas or 
pituitary resistance to thyroid hormone action) (73). The MRI discloses the pituitary 
adenoma (72). A (99 m) Tc-octreotide scan can be a useful tool for confirming diagnosis of 
TSH-secreting adenoma (76).  
5.4 Management  
Therapy of TSH-secreting adenomas can be accomplished by surgery, radiation therapy, 
and medical treatment with somatostatin analogs or dopamine agonists (70).  
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The major aim is to remove the pituitary tumor and restore euthyroidism. Thus, the first 
therapeutic approach to TSH-secreting pituitary microadenomas should be the 
transsphenoidal or subfrontal adenomectomy, the choice of the route depending on the tumor 
volume and its suprasellar extension. This may be complex because of the occasional marked 
fibrosis of these tumors, possibly related to high expression of basic fibroblast growth factor 
(68, 77). In patients with macroadenomas or invasive pituitary tumors, long-acting 
somatostatin analogs may be an effective therapeutic measure to decrease TSH and thyroid 
hormone secretion (72, 78). Octreotide can control central hyperthyroidism, induce tumor 
shrinkage, and it can be a satisfactory method of preoperative preparation for TSH-secreting 
adenoma (73, 76). Aberrant expression of TRβ4 (a novel thyroid hormone receptor β isoform) 
could possibly contribute to the aberrant secretion of TSH in a TSH-secreting adenoma (79). 
5.5 Outcome 
In the past, about one third of the patients were diagnosed as having a primary 
hyperthyroidism (Graves’ disease) and thus mistakenly were treated with thyroid ablation 
(thyroidectomy and/or radioiodine) (73).  
The increasing frequency and early diagnosis of TSH secreting pituitary adenoma may be 
explained by ultrasensitive methods now used for TSH measurement and progress in 
pituitary imaging, mainly with MRI. This change in the presentation and the state of disease 
at diagnosis and the excellent response to somatostatins has improved the prognosis for this 
uncommon disease (70, 80). 
5.6 Complications 
Failure to recognize the presence of a TSH-secreting adenoma may result in dramatic 
consequences, such as improper thyroid ablation that may cause the pituitary tumor volume 
to further expand (73). 
6. LH and FSH secreting PA 
Recent studies have found that a high proportion of clinically non-functioning pituitary 
adenomas are largely gonadotrope-derived, i.e. produce and secrete low levels of intact 
follicle-stimulating hormone (FSH), luteinizing hormone (LH) or only biologically inert 
alpha- or beta-subunits of these hormones (81, 82). 
6.1 Symptoms 
Gonadotroph adenomas are not typically associated with a clinical syndrome (2). They are 
almost always discovered in patients presenting with  mass effect, including visual field loss 
and headache, hypogonadism, and hypopituitarism (81). Anterior pituitary insufficiency is 
much more frequent than gonadal hyperstimulation such as ovarian hyperstimulation (83), 
testicular enlargement (82), and precocious puberty (81, 84). 
6.2 Epidemiology  
Advances in immunocytochemistry, electron microscopy, cell culture, and molecular 
techniques have demonstrated that 80 to 90% of the clinically nonfunctioning pituitary 
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adenomas are gonadotrope-derived and recently recognized as gonadotropinomas, which 
account for as many as 40 to 50% of all pituitary macroadenomas (81, 84). 
Gonadotropinomas have been reported with increasing frequency in middle-aged men, but 
they are less frequently recognized in women. This could be the result of greater difficulty in 
diagnosis due to the normal increase in serum gonadotropins in postmenopausal women 
(85). 
6.3 Diagnosis 
Both clinical and hormonal characteristics of gonadotropinomas usually make them readily 
distinguishable from pituitary enlargement due to long-standing primary hypogonadism 
(86). A careful analysis of hormone assay results show that baseline concentrations of 
gonadotrophin or their free sub-units are elevated in 30 to 50% of the cases. The GnRH test 
is positive in 75 to 100% of the cases (84). The majority of the cases can be recognized, even 
in postmenopausal women, by the serum LH beta responses to TRH, and some can be 
recognized by the responses of serum FSH and LH (87, 88). 
6.4 Management 
Most gonadotropinomas are now first treated by transsphenoidal surgery, to make an 
attempt to restore vision as quickly as possible, and then by radiation therapy to prevent the 
regrowth of any remaining adenomatous tissue. Radiosurgery using gamma knife, the 
linear accelerator, or proton beam therapy showed promising results, especially for 
controlling residual or recurrent tumors (63, 81). Medical therapy for a gonadotrope 
adenoma with a somatostatin analogs, dopamine agonists, or GnRH agonists and 
antagonists has limited utility but is employed in patients who are unable to undergo 
surgery. They may delay or prevent additional tumor growth (64, 84, 89, 90). Experimental 
therapy with intraoperative local chemotherapy or potential gene therapy requires further 
investigation (81). 
6.5 Outcome & Complications 
Long-term outcomes and complications of gonadotropinomas are similar to those of non-
functioning pituitary adenomas.    
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